Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support production of Sanofi therapies and expand capacity for US-based pharma and biotech manufacturing.
The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and potentially, other IL-36–driven conditions.
Through a strategic, non-profit agreement, Gilead will supply up to two million doses of the long-acting HIV prevention drug across 120 low- and lower-middle-income countries over the next three years.